Loss of Fhit is frequent in stage I non-small cell lung cancer and in the lungs of chronic smokers

Cancer Research

Volumn 59, Issue 19, 1999, Pages 4798-4803

  Tseng, Jennifer E ^a   Kemp, Bonnie L ^a   Khuri, Fadlo R ^a   Kurie, Jonathan M ^a   Lee, Jin Soo ^a   Zhou, Xiao ^a   Liu, Diane ^a   Hong, Waun Ki ^a   Mao, Li ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MICROSATELLITE DNA; PROTEIN FHIT; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHUS BIOPSY; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MALE; METAPLASIA; PRECANCER; PRIORITY JOURNAL; SMOKING; TUMOR SUPPRESSOR GENE;

EID: 0033214597     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. CA Cancer J. Clin., 49: 8-31, 1999.
2. Slaughter, M., and Skejkal, W. A. Field cancerization in oral stratified epithelium: clinical implications of multicentric origin. Cancer (Phila.), 6: 963-968, 1953.
3. Kinzler, K. W., and Vogelstein, B. Lessons from hereditary colorectal cancer. Cell, 87: 159-171, 1996.
4. Minna, J. D. Genetic events in the pathogenesis of lung cancer. Chest, 96: 17S-23S, 1989.
5. Mitsudomi, T., Steinberg, S. M., Nau, M. M., Carbone. D., D'Amico, D., Bodner, S., Oie, H. K., Linnoila, R. I., Mulshine, J. L., Minna, J. D., and Gazdar, A. F. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene, 7: 171-180, 1992.
6. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
7. Rosell, R., Monzo, M., Molina, F., Martinez, E., Pifarre, A., Moreno, I., Mate, J. L., de Anta, J. M., Sanchez, M., and Font, A. K-ras genotypes and prognosis in non-small-cell lung cancer. Ann. Oncol., 6: S15-S20, 1995.
8. Reissmann, P. T., Koga, H., Takahashi, R., Figlin, R. A., Holmes, E. C., Piantadosi, S., Cordon-Cardo, C., and Slamon, D. J. Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group. Oncogene, 8: 1913-1919, 1993.
9. Wu, W., Fan, Y. H., Kemp, B. L., Walsh, G., and Mao, L. Overexpression of cdc25A and cdc25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res., 58: 4082-4085, 1998.
10. Sozzi, G., Veronese, M. L., Negrini, M., Baffa, R., Cotticelli, M. G., Inoue, H., Tornielli, S., Pilotti, S., De Gregorio, L., Pastorino, U., Pierotti, M. A., Ohta, M., Huebner, K., and Croce, C. M. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell, 85: 17-26, 1996.
11. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
12. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Gaeta, P., La Rocca, R., Merlo, G., Chella, A., Angeletti, C. A., Dalla Palma, P., and Bevilacqua, G. Cyclin D1 and retinoblastoma susceptibility gene alterations in non-small cell lung cancer. Int. J. Cancer, 75: 187-192, 1998.
13. Cairns, P., Polascik, T. J., Eby, Y., Tokino, K., Califano, J., Merlo, A., Mao, L., Herath, J., Jenkins, R., Westra, W., et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat. Genet., 11: 210-212, 1995.
14. Ohta, M., Inoue, H., Cotticelli, M. G., Kastury, K., Baffa, R., Palazzo, J., Siprashvili, Z., Mori, M., McCue, P., Druck, T., et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3:8) breakpoint, is abnormal in digestive tract cancers. Cell, 84: 587-597, 1996.
15. Sozzi, G., Tornielli, S., Tagliabue, E., Sard, L., Pezzella, F., Pastorino, U., Minoletti, F., Pilotti, S., Ratcliffe, C., Veronese, M. L., Goldstraw, P., Huebner, K., Croce, C. M., and Pierotti, M. A. Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res., 57: 5207-5212, 1997.
16. Mao, L., Lee, J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippman, S., Hittelman, W., and Hong, W. K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat. Med., 2: 682-685, 1996.
17. Greenspan, D. L., Connolly, D. C., Wu, R., Lei, R. Y., Vogelstein, J. T., Kim, Y. T., Mok, J. E., Munoz, N., Bosch, F. X., Shah, K., and Cho, K. R. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res., 57; 4692-4698, 1997.
18. Hadaczek, P., Siprashvili, Z., Markiewski, M., Domagala, W., Druck, T., McCue, P. A., Pekarsky, Y., Ohta, M., Huebner, K., and Lubinski, J. Absence or reduction of Fhit expression in most clear cell renal carcinomas. Cancer Res., 58: 2946-2951, 1998.
19. Sozzi, G., Pastorino, U., Moiraghi, L., Tagliabue, E., Pezzella, F., Ghirelli, C., Tornielli, S., Sard, L., Huebner, K., Pierotti, M. A., Croce, C. M., and Pilotti, S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res., 58: 5032-5037, 1998.
20. Tomizawa, Y., Nakajima, T., Kohno, T., Saito, R., Yamaguchi, N., and Yokota, J. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res., 58: 5478-5483, 1998.
21. Mimori, K., Druck, T., Inoue, H., Alder, H., Berk, L., Mori, M., Huebner, K., and Croce, C. M. Cancer-specific chromosome alterations in the constitutive fragile region FRA3B. Proc. Natl. Acad. Sci. USA, 96: 7456-7461, 1999.
22. Knudson, A. G., Jr. Retinoblastoma: a prototypic hereditary neoplasm. Semin. Oncol., 5: 57-60, 1978.
23. Fong, K. M., Biesterveld, E. J., Virmani, A., Wistuba, I., Sekido, Y., Bader, S. A., Ahmadian, M., Ong, S. T., Rassool, F. V., Zimmerman, P. V., Giaccone, G., Gazdar, A. F., and Minna, J. D. FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. Cancer Res., 57: 2256-2267, 1997.
24. Nelson, H. H., Wiencke, J. K., Gunn, L., Wain, J. C., Christiani, D. C., and Kelsey, K. T. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos. Cancer Res., 58: 1804-1807, 1998.
25. Panagopoulos, I., Thelin, S., Mertens, F., Mitelman, F., and Aman, P. Variable FHIT transcripts in non-neoplastic tissues. Genes Chromosomes Cancer, 19: 215-219, 1997.
26. Chen, Y. J., Chen, P. H., Lee, M. D., and Chang, J. G. Aberrant FHIT transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract. Int. J. Cancer, 72: 955-958, 1997.
27. Gayther, S. A., Barski, P., Batley, S. J., Li, L., de Foy, K. A., Cohen, S. N., Ponder, B. A., and Caldas, C. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours. Oncogene, 15: 2119-2126, 1997.
28. Mao, L., Fan, Y. H., Lotan, R., and Hong, W. K. Frequent abnormalities of FHIT, a candidate tumor suppressor gene, in head and neck cancer cell lines. Cancer Res., 56: 5128-5131, 1996.
29. Druck, T., Kastury, K., Hadaczek, P., Podolski, J., Toloczko, A., Sikorski, A., Ohta, M., LaForgia, S., Lasota, J., McCue, P., Lubinski, J., and Huebner, K. Loss of heterozygosity at the familial RCC t(3:8) locus in most clear cell renal carcinomas. Cancer Res., 55: 5348-5353, 1995.
30. Virgilio, L., Shuster, M., Gollin, S. M., Veronese, M. L., Ohta, M., Huebner, K., and Croce, C. M. FHIT gene alterations in head and neck squamous cell carcinomas. Proc. Natl. Acad. Sci. USA, 93: 9770-9775, 1996.
31. Druck, T., Hadaczek, P., Fu, T. B., Ohta, M., Siprashvili, Z., Baffa, R., Negrini, M., Kastury, K., Veronese, M. L., Rosen, D., Rothstein, J., McCue, P., Cotticelli, M. G., lnoue, H., Croce, C. M., and Huebner, K. Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res., 57: 504-512, 1997.
32. Siprashvili, Z., Sozzi, G., Barnes, L. D., McCue, P., Robinson, A. K., Eryomin, V., Sard, L., Tagliabue, E., Greco, A., Fusetti, L., Schwartz, G. Pierotti, M. A., Croce, C. M., and Huebner, K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc. Natl. Acad. Sci. USA, 94: 13771-13776, 1997.
33. Ji, L., Fang, B., Yen, N., Fong, K., Minna, J. D., and Roth, J. A. Induction of apoptosis, inhibition of tumorigenicity, and suppression of tumor growth by adeno-virus vector-mediated FHIT gene overexpression in vitro and in vivo. Cancer Res., 59: 3333-3339, 1999.
34. Wistuba, I. I., Lam, S., Behrens, C., Virmani, A. K., Fong, K. M., LeRiche, J., Samet, J. M., Srivastava, S., Minna, J. D., and Gazdar, A. F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst., 89: 1366-1373, 1997.
35. Mao, L., Lee, J. S., Kurie, J. M., Fan, Y. H., Lippman, S. M., Lee, J. J., Ro, J. Y., Broxson, A., Yu, R., Morice, R. C., Kemp, B. L., Khuri, F. R., Walsh, G. L., Hittelman, W. N., and Hong, W. K. Clonal genetic alterations in the lungs of current and former smokers. J. Natl. Cancer Inst., 89: 857-862, 1997.
36. Huebner, K., Garrison, P. N., Barnes, L. D., and Croce, C. M. The role of the FHIT/FRA3B locus in cancer. Annu. Rev. Genet., 32: 7-31, 1998.
37. Alavanja, M. C., Brownson, R. C., Benichou, J., Swanson, C., and Boice, J. D., Jr. Attributable risk of lung cancer in lifetime nonsmokers and long-term ex-smokers (Missouri, United States). Cancer Causes Control, 6: 209-216, 1995.
38. Tong, L., Spitz, M. R., Fueger, J. J., and Amos, C. A. Lung carcinoma in former smokers. Cancer (Phila.), 78: 1004-1010, 1996.
39. Tanaka, H., Shimada, Y., Harada, H., Shinoda, M., Hatooka, S., Imamura, M., and Ishizaki, K. Methylation of the 5′ CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res., 58: 3429-3434, 1998.
40. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V , Yew, P. R., Draetta, G. F., and Rolfe, M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (Washington DC), 269: 682-685, 1995.
41. Ong, S. T., Fong, K M., Bader, S. A., Minna, J. D., Le Beau, M. M., McKeithan, T. W., and Rassool, F. V. Precise localization of the FHIT gene to the common fragile site at 3p14.2 (FRA3B) and characterization of homozygous deletions within FRA3B that affect FHIT transcription in tumor cell lines. Genes Chromosomes Cancer, 20: 16-23, 1997.
42. van den Berg, A., Draaijers, T. G., Kok, K., Timmer, T., Van der Veen, A. Y., Veldhuis, P. M., de Leij, L., Gerhartz, C. D., Naylor, S. L., Smith, D. I., and Buys, C. H. Normal FHIT transcripts in renal cell cancer- and lung cancel-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. Genes Chromosomes Cancer, 19: 220-227, 1997.